Join the club for FREE to access the whole archive and other member benefits.

Marco Demaria

Group Leader and Associate Professor at European Research Institute for the Biology of Ageing (ERIBA).

Marco is an Associate Professor in Cellular Ageing at the Medical Faculty of the University of Groningen. Marco obtained his PhD in Molecular Medicine at the University of Torino, Italy, under the supervision of prof. Valeria Poli. In Poli’s lab, he characterized the role of the transcription factor STAT3 as a master regulator of cancer cell survival and metabolism.  He joined the laboratory of prof. Judith Campisi at the Buck Institute for Research on Aging, California USA, in the summer of 2010. In the Campisi lab he developed tools and models to analyze senescent cells in vivo, and characterized the biological functions of senescent cells in tissue repair, cancer and aging. He also started to be interested in therapeutic approaches to target senescent cells to improve healthspan. He joined the University of Groningen and the European Research Institute for the Biology of Ageing (ERIBA) in September 2015 as an Assistant Professor and Group leader of the laboratory “Cellular Senescence and Age-related Pathologies”. In 2018 he co-founded a start-up company, Cleara Biotech, devoted to develop anti-senescence drugs. Dr Demaria also serves as academic editor for Aging Cell, Frontiers in Oncology and Plos One.

Visit website: http://eriba.umcg.nl/people/marco-demaria/

 marcodemariabiotech

 marc_dema

See also: Academia University of Groningen - Public Research university.

Details last updated 21-Nov-2020

Marco Demaria is also referenced in the following:

ARDD 2022 - 9th Aging Research and Drug Discovery Meeting

29-Aug-2022 to 02-Sep-2022

Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen

Marco Demaria News

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Read more...